BCTX vs. FNCH, QTTB, ALVR, LSTA, LIXT, TAOX, ABP, IXHL, CYCC, and MTEX
Should you be buying Briacell Therap stock or one of its competitors? The main competitors of Briacell Therap include Finch Therapeutics Group (FNCH), Q32 Bio (QTTB), AlloVir (ALVR), Lisata Therapeutics (LSTA), Lixte Biotechnology (LIXT), Synaptogenix (TAOX), Abpro (ABP), Incannex Healthcare (IXHL), Cyclacel Pharmaceuticals (CYCC), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry.
Briacell Therap vs. Its Competitors
Briacell Therap (NASDAQ:BCTX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 5.7% of Briacell Therap shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Briacell Therap has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Briacell Therap presently has a consensus price target of $320.00, indicating a potential upside of 4,021.06%. Given Briacell Therap's stronger consensus rating and higher possible upside, research analysts clearly believe Briacell Therap is more favorable than Finch Therapeutics Group.
Finch Therapeutics Group's return on equity of -69.14% beat Briacell Therap's return on equity.
In the previous week, Briacell Therap's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.
Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.
Summary
Finch Therapeutics Group beats Briacell Therap on 6 of the 11 factors compared between the two stocks.
Get Briacell Therap News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Briacell Therap Competitors List
Related Companies and Tools
This page (NASDAQ:BCTX) was last updated on 9/10/2025 by MarketBeat.com Staff
Free BCTX Stock Alerts